Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $190.75M rose 68267.7% year over year, ahead of the +360.2% change in trailing-twelve-month financing cash flow. Sequentially, it rose 953630.0% from the prior quarter.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +68267.7% holds above the trailing-twelve-month pace of +360.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$190.75M+953630.0% QoQ
Last fiscal yearDec 2025
$36.43M-25.7% YoY
LTMMar 2026
$226.9M+360.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68267.7%——
1 year-25.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
36.43M USD
Year-over-year change
-25.7%
4-year CAGR
-12.5%

Financing Cash Flow vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +360.2% is the 5th highest of 8, against a peer median of +4594.2%.
CRVS Competitors
Financing Cash Flow for CRVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTRNektar TherapeuticsLTM Jun 2026$1.07B USD+342086.6%+392.9%1968.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$344.93M USD+4594.2%+454.4%970.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026$313M USD+30.4%+145.5%267.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$226.9M USD+360.2%——
CHRSCoherus Oncology, Inc.LTM Mar 2026$219.85M USD+16.9%—468.9%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$133.79M USD+14802.1%+19.6%—
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M USD+16083.5%+247.3%44.3%
IPHAInnate Pharma S.A.FY2025€5.83M EUR+197.0%—209.2%
ADAGAdagene Inc.LTM Jun 2024$2.15M USD—-37.1%264.1%
CGENCompugen Ltd.LTM Dec 2025$0 USD—+210.9%0.0%
Peer median (excluding CRVS) —+4594.2%+210.9%265.8%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Depreciation & Amortization460K367K151K85K105K
Deferred Income Tax00000
Stock-Based Compensation4.23M2.69M2.15M3M5.33M
Change in Working Capital(3.24M)1.41M(3.59M)(1.65M)3.58M
Accounts Receivables(507K)(81K)562K(49K)38K
Inventory00000
Accounts Payables(1.9M)411K(451K)1.06M(91K)
Other Working Capital(827K)1.08M(3.71M)(2.66M)3.63M
Other Non-Cash Items5.07M9.81M4.39M35.43M(26.53M)
Operating Cash Flow(36.72M)(27.02M)(23.94M)(25.42M)(32.8M)
Capital Expenditures(5K)(269K)(34K)0(174K)
Acquisitions (Net)(21.57K)22K05K0
Purchases of Investments(9.36M)(66.19M)(47.05M)(70.12M)(91.75M)
Sales of Investments30.92M43.16M62.62M42.63M84.13M
Other Investing Activities21.57K0000
Investing Cash Flow21.56M(23.28M)15.54M(27.48M)(7.8M)
Debt Repayment00000
Common Stock Issued60.94M07.84M16.41M36.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.22M012K32.62M0
Financing Cash Flow62.16M07.86M49.03M36.43M
Effect of Forex Changes00000
Net Change in Cash47M(50.3M)(539K)(3.88M)(4.16M)
Free Cash Flow(36.72M)(27.29M)(23.97M)(25.42M)(32.97M)

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.